Ilina is a life sciences expert with over a decade of experience working with pharmaceutical, biotech and diagnostics organizations to create innovative product strategies and grow their portfolios.
Ilina brings 15 years of experience in life sciences strategy consulting. Ilina guides leadership teams through research and development (R&D) portfolio planning, licensing, merger and acquisition opportunity identification, prioritization and valuation, and commercial and market access strategies for products throughout their life cycle. Her experience spans across therapeutic areas, with a focus in oncology, immune/inflammatory disorders, renal disorder, cardiovascular diseases and rare diseases. She has served a range of organizations, including top global biopharmaceutical companies, smaller biotech companies, and diagnostic firms.
Throughout her career, Ilina has:
- Led numerous competitive simulation workshops focused on prioritizing cross-functional launch tactics and defensive strategies against key competitors.
- Created a portfolio prioritization strategy for a leading immune-oncology organization, based on an in-depth review of market opportunity, competitive investments, emerging shifts in the landscape, mechanistic rationale, market access and geographical variables.
- Developed disease area strategies and scenario planning playbooks for a number of global pharmaceutical organizations.
- Supported the visioning, strategic planning and implementation of an enterprisewide access and support services program for a global pharmaceutical organization with a broad portfolio of assets.
Prior to joining Huron, Ilina worked as a life sciences strategy senior consultant at Frankel Group for eight years. She has also worked as a consultant at Quintiles Transnational in its strategic research services group. She began her career as a research associate at the National Cancer Institute.